<DOC>
	<DOCNO>NCT01234012</DOCNO>
	<brief_summary>The purpose study assess safety administer repeated dos IMF-001 , vaccine , patient solid tumor express NY-ESO-1 antigen . If vaccine therapeutically useful , second goal establish maximum therapeutic dose treat patient NY-ESO-1 positive cancer .</brief_summary>
	<brief_title>Study IMF-001 Patients With Malignancies Expressing NY-ESO-1</brief_title>
	<detailed_description>NY-ESO-1 isolate serological analysis recombinant cDNA expression library ( SEREX ) , use tumor mRNA autologous serum esophageal cancer patient . Reverse transcription-polymerase chain reaction ( RT-PCR ) analysis show NY-ESO-1 display typical expression pattern cancer testis antigen ( CT antigens ) . NY-ESO-1 mRNA express testis normal tissue test various type cancer , include lung cancer , breast cancer , malignant melanoma bladder cancer . Since testis immune privilege organ HLA molecule express , antigen consider tumor-specific . IMF-001 CHP-NY-ESO-1 complex consist recombinant NY-ESO-1 protein cholesteryl hydrophobized pullulan ( CHP ) . CHP form colloidally stable nanoparticles water complex substrate NY-ESO-1 protein . It well know exogenous antigen protein induce specific CD4+ T cell specific CD8+ T cell . Dendritic cell pulse IMF-001 induce NY-ESO-1 specific CD8+ T cell blood sample 4 healthy volunteer . These data suggest immunization patient IMF-001 evoke specific CD4+ T cell response also specific CD8+ T cell response NY-ESO-1 effectively NY-ESO-1 protein alone . Similar result cellular humoral immunity response NY-ESO-1 protein observe previous clinical investigational study IMF-001 .</detailed_description>
	<criteria>1 . Patients histologically proven progressive metastatic solid tumor express NYESO1 , fail standard treatment effective treatment available ( solid tumor melanoma , breast cancer , ovarian cancer , prostate cancer , esophageal cancer , uterine cancer , sarcoma frequently express NYESO1 ) . Patients malignant melanoma stage IIb III , stage IV melanoma completely resect , stage I II uterine serous cancer , clear cell carcinoma , carcinosarcoma document expression NYESO1 may also enroll 50 % great chance develop recurrent disease . 2 . Documentation tumor cell express NYESO1 antigen determine immunohistochemistry . 3 . Must target lesion ( ) measurable nonmeasurable RECIST version 1.1 . Exceptions : Patients stage IIb III melanoma , stage IV melanoma completely resect , target lesion measurable RECIST version 1.1 may enroll ; patient prostate cancer without measurable disease rise prostate specific antigen ( PSA ) level may enroll ; patient resect stage I II uterine serous cancer , clear cell carcinoma , carcinosarcoma target lesion measurable RECIST may enroll . 4 . Has recover acute adverse effect prior therapy , exception alopecia . 5 . Laboratory value within follow limit : Hemoglobin ≥ 8.0 g/dL WBC count ≥ 2.0 x 10^9/L ANC ≥ 1.0 x 10^9/L Platelet count ≥ 75 x 10^9/L Serum creatinine ≤ 1.5 mg/dL AST &amp; ALT ≤ 2.5 x ULN ( ≤ 5 x ULN hepatic metastasis ) Serum total bilirubin ≤ 1.5 x ULN 6 . Performance status 0 1 ( ECOG Scale ) . 7 . Life expectancy ≥ 4 month . 8 . Ages 18 year . 9 . Patients central nervous system metastasis may include treat stable 2 month without need administration steroid . Patients unstable metastatic CNS disease exclude . 10 . A negative pregnancy test must document screening/baseline visit woman childbearing potential . A female patient childbearing potential , male patient female partner childbearing potential , must use least one form Investigatorapproved contraception onstudy least 1 month last administration study therapy . 11 . Able willing give write informed consent . 1 . Clinically significant heart disease ( NYHA Class III IV ) . 2 . Serious active infection require antibiotic . 3 . Bleeding disorder . 4 . Unstable metastatic disease central nervous system . 5 . Concomitant systemic treatment corticosteroid . Topical steroid permit . 6 . History severe lifethreatening hypersensitivity allergic reaction . 7 . Known HIV infection . 8 . History immunodeficiency disease autoimmune disease , include scleroderma , Sjögren 's syndrome , lupus erythematosus , idiopathic thrombocytopenic purpura ( ITP ) , multiple sclerosis , rheumatoid arthritis . 9 . Has receive anticancer chemotherapy , immunotherapy , radiotherapy investigational agent within 4 week ( 6 week nitrosoureas mitomycin C ) prior enrollment . Concomitant immunosuppressive therapy permit . Adjuvant interferon alpha allow patient stage IIb , III IV melanoma . Prostate cancer patient PSA recurrence may previous androgen deprivation therapy , provide 4 week washout period observe . 10 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>breast cancer</keyword>
	<keyword>ovarian cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>esophageal cancer</keyword>
	<keyword>uterine cancer</keyword>
	<keyword>sarcoma</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>